查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1971881

生物製劑契約製造市場分析及預測（至2035年）：類型、產品、服務、技術、應用、最終用戶、製程、安裝類型、設備和階段

Biologics Contract Manufacturing Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Application, End User, Process, Installation Type, Equipment, Stage
出版日期: | 出版商: Global Insight Services | 英文 392 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

生物製藥契約製造市場預計將從2024年的289億美元成長到2034年的579億美元，複合年成長率約為7.2%。生物製藥契約製造市場包括為生產單株抗體、疫苗和細胞療法等生物藥物提供第三方服務。這些製造商憑藉其在複雜生物製程方面的專業知識，確保產品品質和合規性。對生物製藥需求的成長和生物製藥領域的創新正在推動市場成長，並凸顯生物製程的擴充性、成本效益和技術進步的重要性。

生物製藥契約製造市場正經歷強勁成長，這主要得益於市場對生物製藥和個人化藥物日益成長的需求。單株抗體細分市場因其療效顯著且在慢性病治療中應用廣泛，成為成長最快的細分市場。重組蛋白細分市場緊隨其後，受益於蛋白質工程技術的進步和生物相似藥產品線的不斷擴展。在服務領域，製程開發服務表現最佳，反映了市場對最佳化生產流程和具成本效益製造解決方案的需求。分析和品管服務緊隨其後，凸顯了嚴格遵守法規和品質保證在生物製藥生產中的重要性。一次性系統和連續生產等先進技術的興起，正在提高生產效率和擴充性。製藥公司與契約製造之間的策略聯盟和夥伴關係日益普遍，推動了創新並拓展了雙方的能力。市場發展的特點是注重永續生產實踐和數位化解決方案的整合，以提高營運效率。

市場區隔
類型 哺乳動物、微生物、酵母、昆蟲、植物、藻類、無細胞系統、連續生產、一次性系統
產品 單株抗體、重組蛋白、疫苗、基因治療、細胞治療、抗體藥物複合體、生物相似藥、血液製品
服務 製程開發、分析和品管測試、細胞株開發、上游工程生產、下游生產、填充和表面處理工程、法規支援、包裝
科技 表達系統、上游工程、下游製程、製劑、冷凍乾燥
適應症 腫瘤學、免疫學、心血管疾病、感染疾病、神經病學、內分泌學、眼科學、血液學
最終用戶 製藥公司、生技公司、研究機構、受託研究機構
過程 間歇式、連續式和混合式工藝
安裝類型 新建設施，維修設施
裝置 生物反應器、離心機、層析法系統、過濾系統、混合系統
步 臨床前、臨床、商業化

市場概況：

生物製劑契約製造市場正經歷激烈的市場佔有率變化，這主要受價格競爭和新產品上市激增的推動。各公司正利用策略聯盟擴大市場佔有率，同時生物製劑生產技術的創新也樹立新的產業標準。對具成本效益、高品質生產解決方案的需求正在推動市場成長，北美和歐洲市場處於領先地位。由於投資增加和政府政策利好，亞太地區正崛起為一個充滿潛力的市場。生物製藥契約製造市場的競爭日益激烈，主要企業正致力於技術創新和產能擴張。監管因素，尤其是在北美和歐洲，對市場動態的形成至關重要。這些法規確保了品質和安全標準，並影響競爭格局。該市場高度集中，主要企業透過併購擴大其全球業務版圖。生物製藥和生物相似藥的創新正在推動市場進一步成長，為其帶來光明前景。

主要趨勢和促進因素：

生物製藥契約製造市場正經歷強勁成長，這主要得益於市場對生物製藥和個人化藥物需求的不斷成長。關鍵趨勢包括生物相似藥的興起，這推動了對具成本效益生產解決方案的需求。細胞和基因療法的進步也促進了市場擴張，因為這些治療方法需要專業的生產能力。製藥公司轉向外包是關鍵促進因素，這使它們能夠在專注於自身核心競爭力的同時，並利用專業的生產技術。此外，監管機構對生物製藥開發的支持也推動了市場成長。新興市場具有成本優勢和不斷擴大的產能，使其成為契約製造盈利日益豐厚的目的地。一次性系統和連續生產等技術進步提高了生產效率和柔軟性。對品質和合規性的日益重視推動了對先進設施的投資。隨著全球生物製藥格局的演變，契約製造可以透過提供創新解決方案和擴展服務組合，最大限度地把握機會。

限制與挑戰：

生物製劑契約製造市場面臨許多重大限制和挑戰。首先，生物製劑生產高成本仍是一大障礙。這需要對先進技術和熟練勞動力進行大量投資，這可能會阻礙中小企業進入市場。其次，生物製劑生產流程的複雜性構成了一項重大挑戰。嚴格的品管和法規遵循要求對許多公司來說都是一項挑戰。此外，生物製劑漫長的監管核准流程可能會延遲市場進入並增加成本。第三，市場面臨熟練專業人員短缺的問題。生物製藥生產的特殊性需要目前供應有限的專業知識。智慧財產權問題也構成挑戰，迫使公司謹慎應對複雜的專利環境以避免訴訟。最後，原物料價格波動會影響生物製藥生產的盈利，增加市場的財務不確定性。

目錄

第1章執行摘要

第2章 市場亮點

第3章 市場動態

  • 宏觀經濟分析
  • 市場趨勢
  • 市場促進因素
  • 市場機遇
  • 市場限制
  • 複合年均成長率：成長分析
  • 影響分析
  • 新興市場
  • 技術藍圖
  • 戰略框架

第4章 細分市場分析

  • 市場規模及預測：依類型
    • 哺乳動物系統
    • 微生物
    • 酵母菌
    • 昆蟲
    • 植物
    • 藻類
    • 無細胞系統
    • 連續製造
    • 免洗系統
  • 市場規模及預測：依產品分類
    • 單株抗體
    • 重組蛋白
    • 疫苗
    • 基因治療
    • 細胞療法
    • 抗體藥物複合體（ADC）
    • 生物相似藥
    • 血液製品
  • 市場規模及預測：依服務分類
    • 製程開發
    • 分析和品管(QC) 測試
    • 細胞株構建
    • 上游工程製造
    • 下游製造
    • 填充和表面處理工程
    • 監管支持
    • 包裝
  • 市場規模及預測：依技術分類
    • 表達系統
    • 上游工程
    • 下游工藝
    • 配方
    • 冷凍乾燥
  • 市場規模及預測：依應用領域分類
    • 腫瘤學
    • 免疫學
    • 心血管疾病
    • 感染疾病
    • 神經病學
    • 內分泌學
    • 眼科
    • 血液學
  • 市場規模及預測：依最終用戶分類
    • 製藥公司
    • 生技公司
    • 研究所
    • 合約研究機構
  • 市場規模及預測：依製程分類
    • 大量生產
    • 連續製造
    • 混合工藝
  • 市場規模及預測：依安裝類型分類
    • 新設施
    • 現有設施的維修
  • 市場規模及預測：依設備分類
    • 生物反應器
    • 離心機
    • 層析法系統
    • 過濾系統
    • 混合系統
  • 市場規模及預測：依製造階段分類
    • 非臨床試驗
    • 臨床
    • 商業的

第5章 區域分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲地區
  • 亞太地區
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲
    • 台灣
    • 亞太其他地區
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 義大利
    • 其他歐洲地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 撒哈拉以南非洲
    • 其他中東和非洲地區

第6章 市場策略

  • 需求與供給差距分析
  • 貿易和物流限制
  • 價格、成本和利潤率趨勢
  • 市場滲透率
  • 消費者分析
  • 法規概述

第7章 競爭訊息

  • 市場定位
  • 市場占有率
  • 競爭基準
  • 主要企業的策略

第8章：公司簡介

  • Samsung Biologics
  • Lonza Group
  • WuXi Biologics
  • Catalent
  • Boehringer Ingelheim Biopharmaceuticals
  • Fujifilm Diosynth Biotechnologies
  • AGC Biologics
  • Jubilant HollisterStier
  • Abzena
  • KBI Biopharma
  • Rentschler Biopharma
  • Samsung Biologics
  • Althea CMO
  • Cytovance Biologics
  • Avid Bioservices

第9章：關於我們

簡介目錄
Product Code: GIS33676

Biologics Contract Manufacturing Market is anticipated to expand from $28.9 billion in 2024 to $57.9 billion by 2034, growing at a CAGR of approximately 7.2%. The Biologics Contract Manufacturing Market encompasses third-party services for producing biologic drugs, including monoclonal antibodies, vaccines, and cell therapies. These manufacturers offer expertise in complex biologic processes, ensuring quality and compliance. Rising biologics demand and biopharmaceutical innovation drive market growth, emphasizing scalability, cost-efficiency, and technological advancements in bioprocessing.

The Biologics Contract Manufacturing Market is experiencing robust growth, propelled by the increasing demand for biologic drugs and personalized medicine. The monoclonal antibodies segment is the top-performing sub-segment, driven by their therapeutic efficacy and broad application in treating chronic diseases. The recombinant proteins segment follows closely, benefiting from advancements in protein engineering and a growing pipeline of biosimilars. Within the service segment, process development services lead in performance, reflecting the need for optimized production processes and cost-effective manufacturing solutions. Analytical and quality control services are the second-highest performers, underscoring the importance of stringent regulatory compliance and quality assurance in biologics production. The rise of advanced technologies, such as single-use systems and continuous manufacturing, is enhancing production efficiency and scalability. Strategic collaborations and partnerships between pharmaceutical companies and contract manufacturers are becoming increasingly prevalent, driving innovation and expanding capabilities. The market's evolution is marked by a focus on sustainable manufacturing practices and the integration of digital solutions to enhance operational efficiency.

Market Segmentation
TypeMammalian, Microbial, Yeast, Insect, Plant, Algae, Cell-Free Systems, Continuous Manufacturing, Single-Use Systems
ProductMonoclonal Antibodies, Recombinant Proteins, Vaccines, Gene Therapy, Cell Therapy, Antibody-Drug Conjugates, Biosimilars, Blood Products
ServicesProcess Development, Analytical and QC Studies, Cell Line Development, Upstream Manufacturing, Downstream Manufacturing, Fill and Finish Operations, Regulatory Support, Packaging
TechnologyExpression Systems, Upstream Processing, Downstream Processing, Formulation, Lyophilization
ApplicationOncology, Immunology, Cardiovascular Diseases, Infectious Diseases, Neurology, Endocrinology, Ophthalmology, Hematology
End UserPharmaceutical Companies, Biotechnology Companies, Research Institutes, Contract Research Organizations
ProcessBatch Manufacturing, Continuous Manufacturing, Hybrid Process
Installation TypeNew Facilities, Retrofit Facilities
EquipmentBioreactors, Centrifuges, Chromatography Systems, Filtration Systems, Mixing Systems
StagePreclinical, Clinical, Commercial

Market Snapshot:

The Biologics Contract Manufacturing Market is witnessing a dynamic shift in market share, driven by competitive pricing and a surge in new product launches. Companies are leveraging strategic partnerships to enhance their market presence, while innovation in biologics production is setting new industry benchmarks. The demand for cost-effective and high-quality manufacturing solutions is propelling growth, with North America and Europe at the forefront. Asia-Pacific is emerging as a lucrative region due to increased investments and favorable government policies. Competition in the Biologics Contract Manufacturing Market is intensifying, with key players focusing on technological advancements and capacity expansions. Regulatory influences, particularly in North America and Europe, play a pivotal role in shaping market dynamics. These regulations ensure quality and safety standards, thereby impacting the competitive landscape. The market is characterized by a high degree of consolidation, with major firms expanding their global footprint through mergers and acquisitions. The future landscape is promising, with innovations in biologics and biosimilars driving further growth.

Geographical Overview:

The Biologics Contract Manufacturing Market is experiencing dynamic growth across various regions, each presenting unique opportunities. North America leads the charge, driven by advanced biotechnology infrastructure and substantial investments in biologics development. The presence of major pharmaceutical companies further accelerates market growth. Europe follows closely, with strong regulatory frameworks and a focus on biosimilars bolstering the market. In Asia Pacific, the market is expanding rapidly, propelled by increasing healthcare demands and supportive government policies. Countries like China and India are emerging as lucrative growth pockets due to their cost-effective manufacturing capabilities and growing biopharmaceutical sectors. Latin America and the Middle East & Africa are also witnessing promising growth. In these regions, rising investments in healthcare infrastructure and a burgeoning demand for biologics are key drivers. Brazil in Latin America and the United Arab Emirates in the Middle East are notable emerging countries, recognizing the potential of biologics contract manufacturing to enhance their healthcare landscapes.

Key Trends and Drivers:

The biologics contract manufacturing market is experiencing robust growth, propelled by increasing demand for biologic drugs and personalized medicine. Key trends include the rise of biosimilars, which are driving the need for cost-effective manufacturing solutions. Advances in cell and gene therapy are also propelling market expansion, as these therapies require specialized production capabilities. The shift towards outsourcing by pharmaceutical companies is a significant driver, allowing them to focus on core competencies while leveraging specialized manufacturing expertise. Additionally, regulatory support for biologics development is fostering market growth. Emerging markets are becoming lucrative destinations for contract manufacturing, offering cost advantages and expanding capabilities. Technological advancements, such as single-use systems and continuous manufacturing, are enhancing production efficiency and flexibility. The focus on quality and compliance is intensifying, prompting investments in state-of-the-art facilities. As the global biologics landscape evolves, contract manufacturers are poised to capitalize on opportunities by offering innovative solutions and expanding their service portfolios.

Restraints and Challenges:

The biologics contract manufacturing market is confronted with several significant restraints and challenges. Firstly, the high cost of biologics production remains a substantial barrier. It demands significant investment in cutting-edge technology and skilled labor, which can deter smaller firms from entering the market. Secondly, the complexity of biologics manufacturing processes presents a formidable challenge. It requires stringent quality control and regulatory compliance, which can be daunting for many companies. Additionally, the lengthy approval processes for biologics by regulatory bodies can delay market entry and increase costs. Thirdly, the market faces a shortage of skilled professionals. The specialized nature of biologics manufacturing necessitates expertise that is currently in limited supply. Furthermore, intellectual property issues pose another challenge, as companies must navigate complex patent landscapes to avoid litigation. Lastly, fluctuating raw material prices can impact the profitability of biologics manufacturing, adding an element of financial uncertainty to the market.

Key Players:

Samsung Biologics, Lonza Group, WuXi Biologics, Catalent, Boehringer Ingelheim Biopharmaceuticals, Fujifilm Diosynth Biotechnologies, AGC Biologics, Jubilant HollisterStier, Abzena, KBI Biopharma, Rentschler Biopharma, Samsung Biologics, Althea CMO, Cytovance Biologics, Avid Bioservices

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Services
  • 2.4 Key Market Highlights by Technology
  • 2.5 Key Market Highlights by Application
  • 2.6 Key Market Highlights by End User
  • 2.7 Key Market Highlights by Process
  • 2.8 Key Market Highlights by Installation Type
  • 2.9 Key Market Highlights by Equipment
  • 2.10 Key Market Highlights by Stage

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Mammalian
    • 4.1.2 Microbial
    • 4.1.3 Yeast
    • 4.1.4 Insect
    • 4.1.5 Plant
    • 4.1.6 Algae
    • 4.1.7 Cell-Free Systems
    • 4.1.8 Continuous Manufacturing
    • 4.1.9 Single-Use Systems
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Monoclonal Antibodies
    • 4.2.2 Recombinant Proteins
    • 4.2.3 Vaccines
    • 4.2.4 Gene Therapy
    • 4.2.5 Cell Therapy
    • 4.2.6 Antibody-Drug Conjugates
    • 4.2.7 Biosimilars
    • 4.2.8 Blood Products
  • 4.3 Market Size & Forecast by Services (2020-2035)
    • 4.3.1 Process Development
    • 4.3.2 Analytical and QC Studies
    • 4.3.3 Cell Line Development
    • 4.3.4 Upstream Manufacturing
    • 4.3.5 Downstream Manufacturing
    • 4.3.6 Fill and Finish Operations
    • 4.3.7 Regulatory Support
    • 4.3.8 Packaging
  • 4.4 Market Size & Forecast by Technology (2020-2035)
    • 4.4.1 Expression Systems
    • 4.4.2 Upstream Processing
    • 4.4.3 Downstream Processing
    • 4.4.4 Formulation
    • 4.4.5 Lyophilization
  • 4.5 Market Size & Forecast by Application (2020-2035)
    • 4.5.1 Oncology
    • 4.5.2 Immunology
    • 4.5.3 Cardiovascular Diseases
    • 4.5.4 Infectious Diseases
    • 4.5.5 Neurology
    • 4.5.6 Endocrinology
    • 4.5.7 Ophthalmology
    • 4.5.8 Hematology
  • 4.6 Market Size & Forecast by End User (2020-2035)
    • 4.6.1 Pharmaceutical Companies
    • 4.6.2 Biotechnology Companies
    • 4.6.3 Research Institutes
    • 4.6.4 Contract Research Organizations
  • 4.7 Market Size & Forecast by Process (2020-2035)
    • 4.7.1 Batch Manufacturing
    • 4.7.2 Continuous Manufacturing
    • 4.7.3 Hybrid Process
  • 4.8 Market Size & Forecast by Installation Type (2020-2035)
    • 4.8.1 New Facilities
    • 4.8.2 Retrofit Facilities
  • 4.9 Market Size & Forecast by Equipment (2020-2035)
    • 4.9.1 Bioreactors
    • 4.9.2 Centrifuges
    • 4.9.3 Chromatography Systems
    • 4.9.4 Filtration Systems
    • 4.9.5 Mixing Systems
  • 4.10 Market Size & Forecast by Stage (2020-2035)
    • 4.10.1 Preclinical
    • 4.10.2 Clinical
    • 4.10.3 Commercial

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Services
      • 5.2.1.4 Technology
      • 5.2.1.5 Application
      • 5.2.1.6 End User
      • 5.2.1.7 Process
      • 5.2.1.8 Installation Type
      • 5.2.1.9 Equipment
      • 5.2.1.10 Stage
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Services
      • 5.2.2.4 Technology
      • 5.2.2.5 Application
      • 5.2.2.6 End User
      • 5.2.2.7 Process
      • 5.2.2.8 Installation Type
      • 5.2.2.9 Equipment
      • 5.2.2.10 Stage
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Services
      • 5.2.3.4 Technology
      • 5.2.3.5 Application
      • 5.2.3.6 End User
      • 5.2.3.7 Process
      • 5.2.3.8 Installation Type
      • 5.2.3.9 Equipment
      • 5.2.3.10 Stage
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Services
      • 5.3.1.4 Technology
      • 5.3.1.5 Application
      • 5.3.1.6 End User
      • 5.3.1.7 Process
      • 5.3.1.8 Installation Type
      • 5.3.1.9 Equipment
      • 5.3.1.10 Stage
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Services
      • 5.3.2.4 Technology
      • 5.3.2.5 Application
      • 5.3.2.6 End User
      • 5.3.2.7 Process
      • 5.3.2.8 Installation Type
      • 5.3.2.9 Equipment
      • 5.3.2.10 Stage
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Services
      • 5.3.3.4 Technology
      • 5.3.3.5 Application
      • 5.3.3.6 End User
      • 5.3.3.7 Process
      • 5.3.3.8 Installation Type
      • 5.3.3.9 Equipment
      • 5.3.3.10 Stage
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Services
      • 5.4.1.4 Technology
      • 5.4.1.5 Application
      • 5.4.1.6 End User
      • 5.4.1.7 Process
      • 5.4.1.8 Installation Type
      • 5.4.1.9 Equipment
      • 5.4.1.10 Stage
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Services
      • 5.4.2.4 Technology
      • 5.4.2.5 Application
      • 5.4.2.6 End User
      • 5.4.2.7 Process
      • 5.4.2.8 Installation Type
      • 5.4.2.9 Equipment
      • 5.4.2.10 Stage
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Services
      • 5.4.3.4 Technology
      • 5.4.3.5 Application
      • 5.4.3.6 End User
      • 5.4.3.7 Process
      • 5.4.3.8 Installation Type
      • 5.4.3.9 Equipment
      • 5.4.3.10 Stage
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Services
      • 5.4.4.4 Technology
      • 5.4.4.5 Application
      • 5.4.4.6 End User
      • 5.4.4.7 Process
      • 5.4.4.8 Installation Type
      • 5.4.4.9 Equipment
      • 5.4.4.10 Stage
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Services
      • 5.4.5.4 Technology
      • 5.4.5.5 Application
      • 5.4.5.6 End User
      • 5.4.5.7 Process
      • 5.4.5.8 Installation Type
      • 5.4.5.9 Equipment
      • 5.4.5.10 Stage
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Services
      • 5.4.6.4 Technology
      • 5.4.6.5 Application
      • 5.4.6.6 End User
      • 5.4.6.7 Process
      • 5.4.6.8 Installation Type
      • 5.4.6.9 Equipment
      • 5.4.6.10 Stage
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Services
      • 5.4.7.4 Technology
      • 5.4.7.5 Application
      • 5.4.7.6 End User
      • 5.4.7.7 Process
      • 5.4.7.8 Installation Type
      • 5.4.7.9 Equipment
      • 5.4.7.10 Stage
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Services
      • 5.5.1.4 Technology
      • 5.5.1.5 Application
      • 5.5.1.6 End User
      • 5.5.1.7 Process
      • 5.5.1.8 Installation Type
      • 5.5.1.9 Equipment
      • 5.5.1.10 Stage
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Services
      • 5.5.2.4 Technology
      • 5.5.2.5 Application
      • 5.5.2.6 End User
      • 5.5.2.7 Process
      • 5.5.2.8 Installation Type
      • 5.5.2.9 Equipment
      • 5.5.2.10 Stage
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Services
      • 5.5.3.4 Technology
      • 5.5.3.5 Application
      • 5.5.3.6 End User
      • 5.5.3.7 Process
      • 5.5.3.8 Installation Type
      • 5.5.3.9 Equipment
      • 5.5.3.10 Stage
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Services
      • 5.5.4.4 Technology
      • 5.5.4.5 Application
      • 5.5.4.6 End User
      • 5.5.4.7 Process
      • 5.5.4.8 Installation Type
      • 5.5.4.9 Equipment
      • 5.5.4.10 Stage
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Services
      • 5.5.5.4 Technology
      • 5.5.5.5 Application
      • 5.5.5.6 End User
      • 5.5.5.7 Process
      • 5.5.5.8 Installation Type
      • 5.5.5.9 Equipment
      • 5.5.5.10 Stage
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Services
      • 5.5.6.4 Technology
      • 5.5.6.5 Application
      • 5.5.6.6 End User
      • 5.5.6.7 Process
      • 5.5.6.8 Installation Type
      • 5.5.6.9 Equipment
      • 5.5.6.10 Stage
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Services
      • 5.6.1.4 Technology
      • 5.6.1.5 Application
      • 5.6.1.6 End User
      • 5.6.1.7 Process
      • 5.6.1.8 Installation Type
      • 5.6.1.9 Equipment
      • 5.6.1.10 Stage
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Services
      • 5.6.2.4 Technology
      • 5.6.2.5 Application
      • 5.6.2.6 End User
      • 5.6.2.7 Process
      • 5.6.2.8 Installation Type
      • 5.6.2.9 Equipment
      • 5.6.2.10 Stage
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Services
      • 5.6.3.4 Technology
      • 5.6.3.5 Application
      • 5.6.3.6 End User
      • 5.6.3.7 Process
      • 5.6.3.8 Installation Type
      • 5.6.3.9 Equipment
      • 5.6.3.10 Stage
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Services
      • 5.6.4.4 Technology
      • 5.6.4.5 Application
      • 5.6.4.6 End User
      • 5.6.4.7 Process
      • 5.6.4.8 Installation Type
      • 5.6.4.9 Equipment
      • 5.6.4.10 Stage
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Services
      • 5.6.5.4 Technology
      • 5.6.5.5 Application
      • 5.6.5.6 End User
      • 5.6.5.7 Process
      • 5.6.5.8 Installation Type
      • 5.6.5.9 Equipment
      • 5.6.5.10 Stage

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Samsung Biologics
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Lonza Group
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 WuXi Biologics
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Catalent
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Boehringer Ingelheim Biopharmaceuticals
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Fujifilm Diosynth Biotechnologies
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 AGC Biologics
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Jubilant HollisterStier
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Abzena
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 KBI Biopharma
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Rentschler Biopharma
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Samsung Biologics
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Althea CMO
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Cytovance Biologics
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Avid Bioservices
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us